Celltrion’s Remsima SC Dominates the German Market with Impressive Growth
Remsima SC increases prescriptions by 10% every year in Germany… Remsima prescriptions also increased, achieving a combined market share of 67%. Begzelma signs exclusive contract with distributor holding 15% share of German bevacizumab market Herzuma surpasses original with 38% market share to become Germany’s No.1 trastuzumab prescription product ‘Remsima SC’, the world’s only infliximab subcutaneous […]
Celtrion Healthcare’s Anticancer Biosimilar Products Gain Success in European Market Expansion
Celltrion Healthcare Expands Presence in Major European Countries with Anticancer Biosimilar Products The CEO of Celltrion Healthcare, Kim Hyeong-gi, disclosed that the company is experiencing significant success in the European market with their anticancer biosimilar products. These products have been consistently winning bids in major European countries and are continuously expanding their performance. Biosimilar for […]
Growth in Sales of Celltrion’s Biosimilars Accelerates with New Product Approvals and Increased Demand
Celltrion Healthcare and Celltrion, two major players in autoimmune disease treatments, have secured a supply agreement worth approximately 423.6 billion won. This contract, the largest quarterly supply deal ever, is driven by the increasing demand for antibody biosimilars in the US and Europe, as well as the recent approvals of Humira biosimilars Uplyma and Begzelma. […]
Celltrion Healthcare Expands Presence in US Market with Biosimilar Avastin ‘Begzelma’ Contracts
Celltrion Healthcare Expands Presence in US Market with Biosimilar Avastin ‘Begzelma’ Celltrion Healthcare, led by CEO Kim Hyung-ki, is rapidly advancing its development into the US market. The company has successfully signed contracts for its biosimilar Avastin, known as ‘Begzelma’, with several large private insurers in the US. Additionally, Celltrion Healthcare has completed the registration […]
